Search Results - "A Madeira, M. I."

P396: DYSREGULATED DNAM‐1 AND KIR2DL1 EXPRESSION IN NATURAL KILLER CELLS CORRELATES WITH POOR OUTCOME IN ACUTE MYELOID LEUKEMIA by F O Costa, A., O Marani, L., A Lopes, I., S Binelli, L., S Scheucher, P., L S Schiavinato, J., A Madeira, M. I., B B Pagnano, K., K Duarte, B., F Glória, A. B., M Rego, E., Traina, F., Welner, R., L Figueiredo‐Pontes, L.

Get full text

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT by O Marani, L., Costa, A., B Silva, F., A Madeira, M. I., S Scheucher, P., L S Schiavinato, J., G Lima, A. S., B B Pagnano, K., K Duarte, B., Freeman, S., M Rego, E., Traina, F., L Figueiredo‐Pontes, L.

Get full text

Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM horse ATG and CY rabbit ATG by Hamerschlak, N, Rodrigues, M, Moraes, D A, Oliveira, M C, Stracieri, A B P L, Pieroni, F, Barros, G M N, Madeira, M I A, Simões, B P, Barreira, A A, Brum, D G, Ribeiro, A A F, Kutner, J M, Tylberi, C P, Porto, P P, Santana, C L, Neto, J Z, Barros, J C, Paes, A T, Burt, R K, Oliveira, E A, Mastropietro, A P, Santos, A C, Voltarelli, J C

“…Studies have shown that autologous hematopoietic SCT (HSCT) can be used as an intensive immunosuppressive therapy to treat refractory patients and to prevent…”
Get full text